title: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
abstract: BACKGROUND
  The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP).
  
  
  METHODS
  We retrospectively analyzed 163 patients with relapsed or refractory diffuse large B-cell lymphoma who received R-ESHAP as salvage therapy with a curative purpose. Patients were divided into two groups according to whether rituximab had been administered (n=94, "R+" group) or not (n=69, "R-" group) prior to R-ESHAP.
  
  
  RESULTS
  Response rates were significantly higher in the R- group in the univariate but not in the multivariate analysis. In the analysis restricted to the R+ group, we observed very low complete remission and overall response rates in patients with primary refractory disease (8% and 33%, respectively), as compared to those in patients who were in first partial remission (41% and 86%) or who had relapsed disease (50% and 75%) (p<0.01 in both cases). Overall, 60% and 65% of patients in the R+ and R- groups, respectively, underwent stem-cell transplantation after the salvage therapy. With a median follow-up of 29 months (range, 6-84), patients in the R+ group had significantly worse progression-free survival (17% vs. 57% at 3 years, p<0.0001) and overall survival (38% v 67% at 3 years, p=0.0005) than patients in the R- group. Prior exposure to rituximab was also an independent adverse prognostic factor for both progression-free survival (RR: 2.0; 95% CI: 1.2-3.3, p=0.008) and overall survival (RR: 2.2; 95% CI: 1.3-3.9, p=0.004).
  
  
  CONCLUSIONS
  R-ESHAP was associated with a high response rate in patients who were not refractory to upfront rituximab-based chemotherapy. However, the survival outcome was poor for patients previously exposed to rituximab, as compared to in those who had not previously been treated with rituximab.
authors.affiliation: Department of Hematology, Complejo Hospitalario de Zamora, Avenida de Requejo 35, Zamora 49022, Spain. amartingar@aehh.org
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martín
authors.forename: Eulogio
authors.initials: E
authors.lastname: Conde
authors.forename: Montserrat
authors.initials: M
authors.lastname: Arnan
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Canales
authors.forename: Guillermo
authors.initials: G
authors.lastname: Deben
authors.forename: Juan M
authors.initials: JM
authors.lastname: Sancho
authors.forename: Rafael
authors.initials: R
authors.lastname: Andreu
authors.forename: Antonio
authors.initials: A
authors.lastname: Salar
authors.forename: Pedro
authors.initials: P
authors.lastname: García-Sanchez
authors.forename: Lourdes
authors.initials: L
authors.lastname: Vázquez
authors.forename: Sara
authors.initials: S
authors.lastname: Nistal
authors.forename: María-José
authors.initials: MJ
authors.lastname: Requena
authors.forename: Eva M
authors.initials: EM
authors.lastname: Donato
authors.forename: José A
authors.initials: JA
authors.lastname: González
authors.forename: Angel
authors.initials: A
authors.lastname: León
authors.forename: Concepción
authors.initials: C
authors.lastname: Ruiz
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.forename: Eva
authors.initials: E
authors.lastname: González-Barca
authors.forename: María-Dolores
authors.initials: MD
authors.lastname: Caballero
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008875:Middle Aged; D012189:Retrospective Studies; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D005047:Etoposide; D003907:Dexamethasone; D002945:Cisplatin